Trial · NCT03735979
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 90-day Utility Weighted Modified Rankin Scores (UW-mRS) | 90 days after randomization | The modified Rankin scale is a 7 point ordinal scale ranging from 0="no symptoms" to 6="death" . For the primary analysis, the scale was analyzed with patient-centered utility weights. We assigned the following utility weights to the seven levels: 10, 9.1,, 7.6, 6.5, 3.3, 0, 0 (with higher scores indicating a better outcome). |
| Secondary | Percentage of Participants With NIHSS Less Than or Equal to 2 at 24 Hours | 24 hours after randomization | National Institute of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating worse neurologic deficit. This is a dichotomous analysis with a cutpoint of 0,1,2 defining the event. |
| Secondary | Change From Baseline to 24-hour NIHSS | 24 hours after randomization | National Institute of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating worse neurologic deficit. |
| Secondary | Percentage of Participants With 90-day mRS 0 or 1 (or Return to Their Historical mRS) | 90 days after randomization | The modified Rankin scale (mRS) is a 7 point scale ranging from 0="no symptoms" to 6="death" where lower scores are better outcomes. For patients with a pre-stroke mRS of greater than 0 or 1, these patients had to return to their historical (pre-stroke) value to be counted as a success. |
| Secondary | Percentage of Participants With 90-day mRS 0, 1 or 2 (or Return to Their Historical mRS) | 90 days after randomization | modified Rankin scale is a 7 point scale ranging from 0="no symptoms" to 6="death" where lower scores are better outcomes. |
| Secondary | 90-day mRS | 90 days after randomization | modified Rankin scale is a 7 point ordinal scale ranging from 0="no symptoms at all" to 6="death" where lower scores are better outcomes. |
| Secondary | 90-day EQ-5D | 90 days after randomization | EuroQol Five-Dimension (EQ-5D) is a measure of health-related quality of life ranging from -0.59 to 1 where 1 is the best possible health state. |
| Secondary | Pre-thrombectomy Modified TICI Score of 2B. | baseline | The modified thrombolysis in cerebral infarction (TICI) score prior to endovascular thrombectomy procedure. The modified pre-thrombectomy TICI score is a 4 point scale with possible values of 0, 1, 2A, and 2B. The values are defined as follows: 0=No flow, 1=Penetration without distal branch filling, 2A=\<50% partial reperfusion, and 2B=50%-99% partial reperfusion. |
| Secondary | Post-thrombectomy Modified TICI Score of 2B or 3 | baseline | The modified thrombolysis in cerebral infarction (TICI) score prior to endovascular thrombectomy procedure. The modified post-thrombectomy TICI score is a 5 point scale with possible values of 0, 1, 2A, 2B, 3. The values are defined as follows: 0=No flow, 1=Penetration without distal branch filling, 2A=\<50% partial reperfusion, 2B=50%-99% partial reperfusion, and 3=Completed reperfusion |
| Other | Symptomatic Intracranial Hemorrhage Within 36 Hours (Primary Safety Outcome) | 36 hours after randomization | Type 2 parenchymal hemorrhage or a parenchymal hemorrhage remote from the area of infarction with neurologic deterioration (defined as an increase of ≥4 points in the NIHSS score)within 36 hours after randomization. |
| Other | Type 1 or Type 2 Parenchymal Hemorrhage Within 36 Hours (Safety Outcome) | 36 hours after randomization | |
| Other | Any Intracranial Hemorrhage Within 36 Hours (Safety Outcome) | 36 hours after randomization | Symptomatic or asymptomatic intracranial hemorrhage within 36 hours of randomization. |
| Other | Other Major Hemorrhage Other Than Intracranial Hemorrhage Within 7 Days (Safety Outcome) | 7 days after randomization | Other major hemorrhage other than intracranial hemorrhage (resulting in the transfusion of \>2 units of packed red cells). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03735979/registered